Well, we will see. First it has to complete phase 1 work. In that time they will scrutinize other nukes for a combo
Picking a companion nuke is a double edged sword.
A weak nuke could mean a weak combo
Sovaldi might mean success for the combo, but could make the drug less affordable.
IF ENTA could partner with or acquire a successful nuke (how many have failed here?), it could have great commercial success.
It has a long way to go, but the slides look very encouraging. There is at least one nuke available commercially (sovaldi) that could make this (potentially) a best in class treatment. I would think this could make ENTA attractive for acquisition, or to partner with.
If it has a viable POC I would think there would be plenty of suitors.
News 
Market Data 
Discover 
